ArticleVeterinary world2025
Fermented black soldier fly larvae as a sustainable replacement for marine fish in Asian swamp eel diets.
Article in Veterinary world, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Fermentation Technology in Aquafeeds: A Review.Microorganisms · 2026Review
- From Science to Innovation in Aquatic Animal Nutrition: A Global TRL-Based Assessment of Insect-Derived Feed Technologies via Scientific Publications and Patents.Animals : an open access journal from MDPI · 2025Article
- Black Soldier Fly Larvae as a Novel Protein Feed Resource Promoting Circular Economy in Agriculture.Insects · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: Fermented black soldier fly larvae (BSFL) have emerged as a sustainable and economically viable protein source in aquaculture. However, their potential as a replacement for marine fish in the diets of Asian swamp eels ( Materials and Methods: A total of 480 ASEs were randomly assigned to four dietary groups: control (40% marine fish), BSFL34 (13.4% BSFL), BSFL61 (24.1% BSFL), and BSFL82 (32.8% BSFL), replacing marine fish on a dry matter basis. All diets were isonitrogenous and isoenergetic. Fish were reared in net cages for over 90 days, and parameters including survival rate, growth metrics, muscle and liver histology, intestinal morphology, gene expression (quantitative real-time polymerase chain reaction), and inflammatory protein levels (Western blotting) were assessed. Results: Survival rate was significantly higher in the BSFL61 group (p < 0.05). Growth performance was not impaired across BSFL-fed groups, although BSFL61 showed reduced body weight compared to BSFL82 (p < 0.05). Muscle fiber size, satellite cell number, and muscle triglyceride (TG) content remained unchanged. BSFL82 showed increased hepatic TG accumulation (p < 0.05) and reduced liver fibrosis, while BSFL61 exhibited a significantly lower hepatosomatic index and increased fibrosis. Intestinal villus height was reduced in BSFL34 and BSFL61, while goblet cell density increased in all BSFL groups. Notch1 expression was upregulated in BSFL61 and BSFL82, whereas ctnnb1 and wnt5a were downregulated. Inflammatory markers nuclear factor-kappa B and interleukin-1 beta were elevated in BSFL-fed groups, indicating an activated mucosal immune response. Conclusion: Partial replacement of marine fish with fermented BSFL enhanced ASE survival, modulated intestinal immunity, and improved mucosal barrier function, without compromising overall growth performance. However, excessive inclusion may induce hepatic lipid accumulation and affect intestinal morphology. These findings support the use of fermented BSFL as a sustainable aquafeed ingredient, though inclusion levels should be carefully optimized to balance health benefits and growth efficiency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.